Reach: research enterprise to advance a cure for HIV

Active Cooperative Agreement Awarded Last action

Award ID
UM1AI164565
Recipient
Awarding agency
Obligated
$22,930,953

Award facts

Completion date 76% complete
Originally
Funding agency
National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Department of Health and Human Services
Place of performance
New York, NY 10065, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Despite the success of standard antiretroviral therapy (art), the need for an HIV cure remains compelling, both to improve the lives of PWH and to bring about the end of the pandemic. Strategies for an HIV cure fall under two categories: those that seek art-free 'REMISSION', and those targeting a classical cure or 'eradication'. While precedents exist for both scenarios, the latter have only been achieved with bone marrow transplantation. In contrast, although naturally occurring immune-mediated control of HIV (REMISSION) is relatively rare, many such cases have been described. Our proposed "martin delaney collaboratory for HIV cure research" program is entitled "reach" - research enterprise to advance a cure for HIV. The central theme of reach is that cellular immune responses (NK and T-cells), combined with next generation virus-neutralizing biologics, can be harnessed to achieve durable REMISSION and eradication of HIV reservoirs. The proposed research focuses on closing gaps in our understanding of the fundamentals of the system that we are trying to perturb, i.e.: the HIV reservoir in relation to cellular immunity, as the means to achieve real progress towards effective and viable HIV cure strategies. Our approach centers around three research foci, which emphasize back to basics science, but connect this with discovery to translational pipelines directed towards both REMISSION and eradication. The proposed objectives, broadly defined, aim to: (1) redefine the three-way relationship between the persistent HIV reservoir, CD8+ T-cells, and rebound virus at the levels of: single cells, individuals, and diverse populations, (2) harness conventional and unconventional (BNAB-INDUCED) CD8+ T-cells responses, in combination with bnabs and 'next generation' biologics, to achieve durable control of HIV replication, and (3) develop a discovery-to- translation pipeline to overcome multiple barriers to the eradication of HIV reservoirs by CTL/NK cells. These studies will be rooted in a strong basic science program that will contextualize results with novel insights into barriers to immune-mediated reservoir elimination, including the role of the proviral integration site and of viral and host factors influencing immune susceptibility. Our program prioritizes the study of diverse populations, including african populations infected with non-B subtype virus, and women - both to advance towards a cure for all, and to benefit from diverse perspectives as a source of fundamental insights. These objectives will be realized by a group of accomplished investigators of diverse expertise and with strong collaborative histories, along with community and industry partners.

Transactions

Action Obligated Date
Amendment $166,667
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $166,667
Amendment $125,000
Amendment $166,667
Amendment $125,000
Amendment Reach: research enterprise to advance a cure for HIV - modified project summary/abstract section despite the success of standard antiretroviral therapy (art),… $125,000
Amendment $4,704,982
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $179,477
Amendment $179,477
Amendment $179,477
Amendment $179,477
Amendment $208,334
Amendment $166,667
Amendment $208,334
Amendment $4,721,261
Amendment $166,667
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $4,811,452
Amendment $125,000
Amendment $208,334
Amendment $166,667
Amendment $166,667
Amendment $5,017,011
Amendment $208,334
Amendment $166,667
Amendment $125,000
Original award $166,667
Show all 45

Subawards

Subrecipient Amount Awarded
The Washington University Dr. Marilia Pinzone is an Assistant Professor at Washington University in the Department of Medicine, Division of Infectious Diseases. Dr. Pinzone has expertise… $93,300
University Of Louisville Melissa Smith, PhD (Subaward Principal Investigator [PI]) (10% FTE [1.20 Calendar Months]) Dr. Smith’s role will be to manage research staff (Graduate… $810,357
Yale Univ Ya-Chi Ho, MD/PhD (Subaward Principal Investigator [PI]) (5% FTE [0.60 Calendar Months]) Dr. Ho has 12 years of experience in HIV genome mapping, from the first… $959,147
The Rockefeller University Additional changes:Attachment 2: Additional Terms - Invoicing: A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be… $5,009,485
Fred Hutchinson Cancer Center Lillian B. Cohn, PhD (Subaward Principal Investigator [PI]) (10% FTE [1.20 Calendar Months]) Dr. Lillian Cohn is an Assistant Professor in the Immunology and… $1,213,344
George Washington University (The) BUDGET JUSTIFICATION GEORGE WASHINGTON UNIVERSITY (GWU) YEAR 4 (YEAR 2 SUBAWARD GWU) PERSONNEL COSTS: Key Personnel Bosque, Alberto, PhD (Co-Investigator)… $726,750
University Of Pittsburgh This Subaward to the University of Pittsburgh (Pitt) from Cornell University will fund important work in support of the scientific agenda of the REACH… $2,101,191
The Trustees Of The University Of Pennsylvania Subawards Total Subawards Amount $6,901,046.00 Last Updated Feb 25, 2026 Reset All Filter By Subaward Subrecipient Subaward Date Status Draft Published Reopened… $40,625
University Of Massachusetts Medical School Kiera Clayton, PhD (Subaward Principal Investigator [PI]) (25% FTE [3.00 Calendar Months]) Dr. Clayton has an Honors Bachelors in Biochemistry and a PhD in… $1,719,533
Charité - Universitätsmedizin Berlin highthroughput quantification of intact HIV proviral DNA, overcoming limitations of existing assays. Overall Goals and Objectives: 1. Develop a novel multicolor… $163,468
University Of Pittsburgh - Of The Commonwealth System Of Higher Education John W. Mellors, MD (Co-Investigator) (10% FTE [1.20 Calendar Months]) Dr. Mellors is a Professor of Medicine at the University of Pittsburgh. On the respective… $1,663,941
Subrecipient not on record Kovacs Colin, MD (Co-Investigator) (8.3% FTE [1.00 Calendar Months]) Dr. Kovacs is a clinician-scientist in Toronto and an Assistant Professor at the University… $135,205
Universitätsklinikum Heidelberg Additional changes:Attachment 2: Additional Terms - Invoicing: A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be… $170,640
Fred Hutchinson Cancer Center Lillian B. Cohn, PhD (Subaward Principal Investigator [PI]) (10% FTE [1.20 Calendar Months]) Dr. Lillian Cohn is an Assistant Professor in the Immunology and… $949,344
The Governing Council Of The University Of Toronto Mario Ostrowski, MD (Co-Investigator (2% FTE [0.24 Calendar Months]) Dr. Ostrowski, a clinician scientist trained in anatomical pathology (McGill), internal… $211,932
Subrecipient not on record Additional changes:Attachment 2: Additional Terms - Invoicing: A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be… $196,953
University Of Western Ontario Jessica Prodger, PhD (Co-Investigator) (10% FTE [1.20 Calendar Months]) Dr. Prodger is a Canada Research Chair with a background in immunology and… $383,501
Aarhus Universitet The overall aim of this work Is to decipher T cell cross-talk among post-treatment controllers and non-controllers following ART interruption. To achieve this… $216,000
The Chancellor Masters & Scholars Of The University Of Oxford Alexander John Frater, PhD (Subaward Principal Investigator [PI]) (5% FTE [0.60 Calendar Months]) Dr. Frater is a Professor of Infectious Diseases in the… $521,728
Subrecipient not on record Kovacs Colin, MD (Co-Investigator) (8.3% FTE [1.00 Calendar Months]) Dr. Kovacs is a clinician-scientist in Toronto and an Assistant Professor at the University… $120,949
Instituto Nacional De Enfermedades Respiratorias The Center for Research in Infectious Diseases (CIENI) at the National Institute of Respiratory Diseases (INER) in Mexico City has access to lymph node and… $142,953
University College Oxford The Frater laboratory has a strong track-record in translational and experimental research in the field of HIV cure and remission, leading clinical trials… $111,328
The Rockefeller University Scope of Work: The Rockefeller University has been asked to serve as a collaborating institution in the REACH – HIV Collaboratory led by Dr. R. Brad… $305,106
Subrecipient not on record Summary: This grant has four initial research foci (IRF) that are aimed at understanding how to enhance the killing ability of HIV specific CTLs, to augment… $30,230
University Of Louisville Dr. Smith’s laboratory will be participating and contributing to the elements of RF1 focused on profiling the HIV transcriptome (TranSeq) with single… $458,443
University Of Massachusetts Medical School Overview This proposed work by Dr. Kiera Clayton at the University of Massachusetts, Department of Pathology, as part of the REACH Martin Delaney… $967,432
Rakai Health Sciences Program The scope of work for the Rakai Health Sciences Program (RHSP) includes two major research goals: the maintenance and continuation of the Uganda latent viral… $320,945
Fred Hutchinson Cancer Center When antiretroviral treatment is interrupted, viremia rebounds from the latent reservoir. Sequencing the plasma virus which rebounds is critical to… $685,344
Universität Heidelberg The Muecksch laboratory at Heidelberg University Hospital in Germany will conduct research related to identifying novel host cell factors contributing to… $255,960
The Governing Council Of The University Of Toronto We will be working with R. Brad Jones laboratory Research Focus 3 –under aim #4: Iterative testing of combination approaches to eliminate HIV… $154,932
University Of Western Ontario At Western University, Dr. Prodger will be responsible for providing support and oversight to investigators at the Rakai Health Sciences Program (RHSP) for… $277,661
Yale Univ A major research focus of The REACH Martin Delaney Collaboratory, led by Dr. Brad Jones and Dr. Marina Caskey, is to identify, characterize, and quantify HIV… $523,647
George Washington University (The) The Lynch lab will be evaluating the relationship between env gene genetic diversity, sensitivity to broadly neutralizing antibodies in order to understand… $242,250
University Of Pittsburgh - Of The Commonwealth System Of Higher Education This Subaward to the University of Pittsburgh (Pitt) from Cornell University will fund important work in support of the scientific agenda of the REACH… $1,226,691
Simon Fraser University The Brumme/Brockman laboratory at SFU will conduct research related to several primary objectives described in RF1 of the grant proposal, including… $619,463
Trustees Of Boston College This project will test the hypothesis that genetically modifying the immune system in order to both more potently recognize HIV, and home directly to the B cell… $695,935
Show all 36

Quick answers

Who received award UM1AI164565?

UM1AI164565 was awarded to Weill Medical College Of Cornell University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 13, 2021.

How much is award UM1AI164565 worth?

$22,930,953 has been obligated on UM1AI164565.

Which agency awarded UM1AI164565?

National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded UM1AI164565, with funding from National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login